Company / EPS (Basic)
CRISPR Therapeutics AG EPS (Basic) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Basic)
-$1.94
FY2025
5-year range
-$8.36 / $4.97
FY2021-FY2025
Trend
+76.8%
vs FY2024
Sector context
#121 of 208
Health Care
What the data says
At $-1.94, CRISPR Therapeutics AG's eps (basic) ranks #121 of 208 in the Health Care sector. EPS (Basic) has fluctuated over the past 10 years, ranging from $-8.36 in FY2024 to $4.97 in FY2023.
Based on SEC 10-K filings.
-1.94 in FY2025.
Declined from $4.97 to $-1.94 over the past 2 years.
Health Care sector context is included.
EPS (Basic) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#121 of 208 in Health CareTop 58% of 208This company -$1.94 Sector average -$1.02
▼
-90.9% below sector average
Key checks
Key Insights
- In FY2025, eps (basic) increased 76.8% year-over-year.
- Ranks #121 out of 208 companies in the Health Care sector.
- Peak eps (basic) was recorded in FY2023.
- Lowest eps (basic) in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Basic)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.94 | +76.8% |
| FY2024 | -$8.36 | -268.2% |
| FY2023 | $4.97 | +194.0% |
| FY2022 | -$5.29 | -530.1% |
| FY2021 | $1.23 | +135.8% |
| FY2020 | -$3.44 | -101.2% |
| FY2019 | -$1.71 | -175.8% |
| FY2018 | -$0.62 | -14.8% |
| FY2017 | -$0.54 | +64.7% |
| FY2016 | -$1.53 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026